Polish Robot in the Operating Room, Polish Ozempic on the Horizon
Warsaw Medical EXPO · weekly review · 2026-10-19
MedTech News

Polish Robot in the Operating Room, Polish Ozempic on the Horizon

This week in Polish medtech proves that homegrown innovation can span everything from orthopedics to endocrinology. On one hand, we have the first-ever procedure performed with a Polish surgical robot; on the other, a real shot at a European generic blockbuster worth billions. Here's what happened and why it's worth following.

01 · Surgical Robotics

MISSO Enters the Operating Room

On October 14, 2026, at the Mazovian Specialist Hospital in Ostrołęka, a new chapter in Polish medicine was written: the country's first total knee replacement procedure assisted by the Polish MISSO robotic system [1]. It's a breakthrough, since until now this type of robot-assisted surgery has relied exclusively on foreign technology.

Behind the system is MedTech Solutions, a company in no mood to rest on its laurels — just two days after the historic procedure, on October 16, it announced a share issue worth up to PLN 15.1 million [1]. The funds raised are earmarked for further development of its robotics and for additional acquisitions, in line with a strategy the company had already signaled when MedTech Solutions acquired Good For You Medical [1]. It's a clear sign that Polish surgical robotics is moving from the R&D phase into commercialization and expansion — good news for the entire domestic medtech sector.

Close-up of a syringe/injection pen needle – a generic illustrative image of injectable medications, fitting the topic of semaglutide-type drugs (not a depiction of Ozempic or Reduzek specifically).
Source: Pixabay · Author: TeemaTuotanto · License: Pixabay Content License

02 · Pharma

Celon Pharma Sets Its Sights on the European Semaglutide Market

If surgical robotics is one face of Polish innovation, pharma shows another — and perhaps an even more spectacular one. Celon Pharma has filed registration applications in more than a dozen EU countries for Reduzek, a generic equivalent of semaglutide, the active substance known from the original Ozempic and Wegovy products [2]. In a bioequivalence study conducted on 91 volunteers, Reduzek showed absorption comparable to the reference drugs [2] — a key piece of evidence that paves the way for registration.

The company isn't stopping at paperwork. In parallel, it is building an active-substance plant in Slovakia, with financial backing from the European Bank for Reconstruction and Development [2]. Sales of Reduzek are slated to begin in 2028, with Celon Pharma planning to target first the markets where patent protection on the original products has already expired [2]. Given that the global market for semaglutide-based drugs is measured in billions of dollars, the Polish company is positioning itself as a genuine contender for a slice of that pie — not just a local player.

Summary

Summary

From a robot operating on knees in Ostrołęka to a generic drug poised to shake up the European pharmaceutical market — this week shows that Polish medtech and Polish pharma can play in the top league. Stories like these are exactly what's worth discussing in person, exchanging experiences over, and building business connections around. Join us at the International Medical Fair – Warsaw Medical Expo (5th edition), where you'll find exhibitors from surgical robotics, pharma, and many other medical fields driving this dynamic change.

Invitation

From orthopedic robotics to the race for the European semaglutide drug market – stories like these are best followed from the front row. Visit the International Medical Fair – Warsaw Medical Expo (5th edition) and meet the companies truly reshaping the Polish medtech and pharma market. It's a chance to talk with medical technology manufacturers and pharmaceutical industry representatives from across the country.

Warsaw Medical Expo 2026

This review was prepared by the Ptak Warsaw Expo editorial team.

Warsaw Medical EXPO · weekly review · 2026-10-19